Tevogen Bio (TVGN) Expected to Announce Quarterly Earnings on Tuesday

Tevogen Bio (NASDAQ:TVGN) is expected to announce its results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.0620) per share for the quarter.

Tevogen Bio Price Performance

Shares of NASDAQ:TVGN opened at $4.36 on Monday. The business’s 50 day moving average is $11.53 and its 200 day moving average is $21.58. The stock has a market cap of $17.66 million, a P/E ratio of -0.46 and a beta of -0.76. Tevogen Bio has a 52-week low of $4.18 and a 52-week high of $75.50.

Institutional Investors Weigh In On Tevogen Bio

A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its stake in Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after buying an additional 130,738 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after buying an additional 33,000 shares in the last quarter.

Wall Street Analyst Weigh In

TVGN has been the topic of a number of recent research reports. D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, January 21st. Finally, Wall Street Zen cut shares of Tevogen Bio to a “strong sell” rating in a report on Saturday, March 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tevogen Bio has a consensus rating of “Reduce” and an average price target of $100.00.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.